Exploring how diverse populations of Pseudomonas aeruginosa develop antibiotic resistance in cystic fibrosis patients
Understanding in vivo antibiotic resistance in diverse Pseudomonas aeruginosa populations
This study is looking at how different types of a harmful germ called Pseudomonas aeruginosa behave and change in cystic fibrosis patients, with the goal of finding out why some of these germs can resist antibiotics, which could help improve treatments for those dealing with stubborn lung infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11054642 on NIH RePORTER |
What this research studies
This research investigates the complex interactions and genetic diversity of Pseudomonas aeruginosa, a harmful bacterium that causes chronic lung infections in cystic fibrosis (CF) patients. By analyzing sputum samples from CF patients, the study aims to understand how variations within bacterial populations contribute to their ability to resist antibiotics. The research will explore factors such as evolutionary trade-offs and social interactions among bacterial strains to uncover the mechanisms behind antibiotic resistance. This knowledge could lead to improved diagnostic and treatment strategies for CF patients suffering from persistent infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis who are experiencing chronic lung infections caused by Pseudomonas aeruginosa.
Not a fit: Patients without cystic fibrosis or those not infected with Pseudomonas aeruginosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cystic fibrosis patients by addressing antibiotic resistance in lung infections.
How similar studies have performed: Previous research has shown that understanding bacterial population dynamics can lead to breakthroughs in treating antibiotic-resistant infections, indicating a promising avenue for this study.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Diggle, Stephen Paul — Georgia Institute of Technology
- Study coordinator: Diggle, Stephen Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.